Source comparison
TB-500 vs Stem Cell Therapy: Clinical Comparison
Mechanism Actin upregulation; promotes cell migration and angiogenesis Introduces pluripotent cells that differentiate into target tissue type TB-500 optimises existing repair; stem cells rebuild lost structure Best For Soft tissue injuries, post-surgical heal
This comparison does not assign a generated winner or score.
- Mechanism
- Actin upregulation; promotes cell migration and angiogenesis
- Introduces pluripotent cells that differentiate into target tissue type
- TB-500 optimises existing repair; stem cells rebuild lost structure
- Best For
- Soft tissue injuries, post-surgical healing, chronic inflammation
- Cartilage defects, tendon tears, degenerative joint disease
- TB-500 for acute/subacute injuries; stem cells for structural loss
- Procedure Type
- Subcutaneous peptide injection (self-administered in research settings)
- Intra-articular or intra-tissue injection (clinical procedure)
- TB-500 non-invasive; stem cells require sterile injection protocol
- Duration of Effect
- 4–8 weeks per cycle; effects diminish after discontinuation
- 6–18 months; some patients report multi-year benefit
- TB-500 shorter-term; stem cells show longer durability
- Cost (Per Treatment Cycle)
- $200–$600 for 4–6 week protocol (research peptide pricing)
- $3,000–$8,000 per injection session
- TB-500 significantly more affordable; stem cells high upfront cost
- Evidence Base
- Limited human trials; most data from animal models and case reports
- Multiple Phase II/III trials in osteoarthritis, tendon repair, cardiac injury
- Stem cells have stronger clinical validation; TB-500 remains experimental